MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-08-2024
Emergent BioSolutions Total Assets 2011-2026 | EBS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Emergent BioSolutions
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.82 B | 3.17 B | 2.96 B | 2.88 B | 2.33 B | 2.23 B | 1.07 B | 970 M | 1.04 B | 945 M | 627 M | 564 M | 547 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.17 B | 547 M | 1.63 B |
Quarterly Total Assets Emergent BioSolutions
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.89 B | 3.17 B | 2.9 B | - | 2.78 B | 2.96 B | 2.87 B | 2.92 B | 2.9 B | 2.88 B | 2.88 B | 2.88 B | 2.88 B | 2.33 B | 2.33 B | 2.33 B | 2.33 B | 2.23 B | 2.23 B | 2.23 B | 2.23 B | 1.07 B | 1.07 B | 1.07 B | 1.07 B | 970 M | 970 M | 970 M | 970 M | 1.04 B | 1.04 B | 1.04 B | 1.04 B | 939 M | 939 M | 939 M | 945 M | 627 M | 627 M | 627 M | 627 M | 564 M | 564 M | 564 M | 564 M | 547 M | 547 M | 547 M | 547 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.17 B | 547 M | 1.57 B |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M |  USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.2 | 1.27 % | $ 129 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
18.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 2.68 | -0.56 % | $ 1.42 B | Canada |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.69 | 0.9 % | $ 402 M | Canada |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | $ 21.48 | -0.12 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
233 M | $ 5.72 | -3.3 % | $ 355 M | USA |
 |
Harrow Health
HROW
|
312 M | $ 50.79 | -5.07 % | $ 1.66 B | USA |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 1.38 | 9.13 % | $ 24.1 M |  China |
 |
Sundial Growers
SNDL
|
1.35 B | $ 1.66 | -1.19 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 3.8 | - | $ 4.72 M | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 7.9 | 3.41 % | $ 2.88 B | Canada |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
223 M | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 5.14 | 8.9 % | $ 72.3 M | USA |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 4.32 | -0.92 % | $ 569 M | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 26.13 | 3.24 % | $ 1.21 B | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 4.23 | -0.25 % | $ 86.3 M | Canada |
 |
Rockwell Medical
RMTI
|
52.2 M | $ 0.95 | 2.85 % | $ 22.2 M | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
9.65 B | $ 14.7 | -0.47 % | $ 2.02 B | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.34 | 0.43 % | $ 316 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 1.11 | -3.91 % | $ 4.79 M | USA |
 |
Relmada Therapeutics
RLMD
|
97.6 M | $ 4.3 | 5.39 % | $ 129 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
286 M | $ 9.35 | -1.86 % | $ 664 M | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
189 M | $ 5.58 | 1.64 % | $ 228 M | USA |
 |
SCYNEXIS
SCYX
|
128 M | $ 0.64 | -0.12 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
4.31 B | $ 8.95 | -3.35 % | $ 5.53 B | Canada |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 2.0 | -2.0 % | $ 20.9 M | USA |
 |
Zomedica Corp.
ZOM
|
253 M | - | -0.21 % | $ 98 M | USA |